ResearcherRoyal Stoke University HospitalActive in the last 2 years

Tejinderjit Athwal

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2300-0735; OpenAlex author ID A5004463017. Sources: OpenAlex.

Their work

Papers: 6 (first author 0, last author 3)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 19

Papers, trials and grants by year

2023: 2 papers · 2024: 3 papers · 2025: none · 2026: 1 paper

Papers 6

Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the European Registry of Hereditary Pancreat… Co-author DOI 10.1016/j.ejca.2026.116592 ↗
The role of adjuvant chemotherapy in management of stage I pancreatic ductal adenocarcinoma deserves independent high quality research. Last author DOI 10.1002/jhbp.1409 ↗
Meta-analysis of adjuvant chemotherapy versus no adjuvant chemotherapy for resected stage I pancreatic cancer. Last author DOI 10.1016/j.surg.2023.11.027 ↗
Meta-analysis of pancreatic re-resection for locally recurrent pancreatic cancer following index pancreatectomy. Last author DOI 10.14701/ahbps.24-041 ↗
The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study. Co-author DOI 10.1038/s41416-023-02220-2 ↗
Preoperative C-Reactive Protein-to-Albumin Ratio and Its Ability to Predict Outcomes of Pancreatic Cancer Resection: A Systematic Review. Co-author DOI 10.3390/biomedicines11071983 ↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shahin Hajibandeh · 4 shared papers, 2023–2024 · strength 1.07
Shahab Hajibandeh · 4 shared papers, 2023–2024 · strength 1.07
Daisy Evans · 2 shared papers, 2024 · strength 0.54
- Paper Meta-analysis of pancreatic re-resection for locally recurrent pancreatic cancer following index pancreatectomy. DOI 10.14701/ahbps.24-041 ↗
- Paper Meta-analysis of adjuvant chemotherapy versus no adjuvant chemotherapy for resected stage I pancreatic cancer. DOI 10.1016/j.surg.2023.11.027 ↗
Annabelle Boughey · 1 shared paper, 2026 · strength 0.22
- Paper Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the … DOI 10.1016/j.ejca.2026.116592 ↗
Paula Ghaneh · 1 shared paper, 2026 · strength 0.22
- Paper Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the … DOI 10.1016/j.ejca.2026.116592 ↗
Mark Taylor · 1 shared paper, 2026 · strength 0.22
- Paper Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the … DOI 10.1016/j.ejca.2026.116592 ↗
Kofi W. Oppong · 1 shared paper, 2026 · strength 0.22
- Paper Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the … DOI 10.1016/j.ejca.2026.116592 ↗
Andrew Malvern Smith · 1 shared paper, 2026 · strength 0.22
- Paper Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the … DOI 10.1016/j.ejca.2026.116592 ↗
Guruprasad Padur Aithal · 1 shared paper, 2026 · strength 0.22
- Paper Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the … DOI 10.1016/j.ejca.2026.116592 ↗
Phillip J. Hopley · 1 shared paper, 2026 · strength 0.22
- Paper Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the … DOI 10.1016/j.ejca.2026.116592 ↗
Zaed Z. R. Hamady · 1 shared paper, 2026 · strength 0.22
- Paper Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the … DOI 10.1016/j.ejca.2026.116592 ↗
William Greenhalf · 1 shared paper, 2026 · strength 0.22
- Paper Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the … DOI 10.1016/j.ejca.2026.116592 ↗
Stephen P. Pereira · 1 shared paper, 2026 · strength 0.22
- Paper Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the … DOI 10.1016/j.ejca.2026.116592 ↗
Christopher Michael Halloran · 1 shared paper, 2026 · strength 0.22
- Paper Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the … DOI 10.1016/j.ejca.2026.116592 ↗
Eithne Costello · 1 shared paper, 2026 · strength 0.22
- Paper Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the … DOI 10.1016/j.ejca.2026.116592 ↗
Thomas Satyadas · 1 shared paper, 2023 · strength 0.17
- Paper Preoperative C-Reactive Protein-to-Albumin Ratio and Its Ability to Predict Outcomes of Pancreatic Cancer Resection: A … DOI 10.3390/biomedicines11071983 ↗
Somaiah Aroori · 1 shared paper, 2023 · strength 0.17
- Paper Preoperative C-Reactive Protein-to-Albumin Ratio and Its Ability to Predict Outcomes of Pancreatic Cancer Resection: A … DOI 10.3390/biomedicines11071983 ↗
Keith John Roberts · 1 shared paper, 2023 · strength 0.17
- Paper Preoperative C-Reactive Protein-to-Albumin Ratio and Its Ability to Predict Outcomes of Pancreatic Cancer Resection: A … DOI 10.3390/biomedicines11071983 ↗
Daren A. Subar · 1 shared paper, 2023 · strength 0.17
- Paper Preoperative C-Reactive Protein-to-Albumin Ratio and Its Ability to Predict Outcomes of Pancreatic Cancer Resection: A … DOI 10.3390/biomedicines11071983 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.